The CD4+ T cells were genetically engineered to express a CAR targeting myelin oligodendrocyte glycoprotein (MOG) in combination with the murine FoxP3 gene, resulting in a reduction of disease symptoms and a decrease in IL-12 and IFN-γ mRNA levels in brain tissue from a murine model of MS (67). Here, MOG is linked to myeloid sarcoma.